• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

黏多糖贮积症 IIIA 型:临床谱及基因型-表型相关性。

Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations.

机构信息

Department of Pediatrics and Amsterdam Lysosome Center Sphinx, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands.

出版信息

Ann Neurol. 2010 Dec;68(6):876-87. doi: 10.1002/ana.22092.

DOI:10.1002/ana.22092
PMID:21061399
Abstract

OBJECTIVE

Mucopolysaccharidosis (MPS) IIIA (Sanfilippo syndrome type A) is a lysosomal storage disorder caused by deficiency of the enzyme sulfamidase. Information on the natural course of MPS IIIA is scarce, but is much needed in view of emerging therapies.

METHODS

Clinical history and molecular defects of all 110 MPS IIIA patients identified by enzymatic studies in the Netherlands were collected and included in this study.

RESULTS

First clinical signs, mainly consisting of delayed speech development and behavioral problems, were noted between the ages of 1 and 6 years. Other symptoms included sleeping and hearing problems, recurrent upper airway infections, diarrhea, and epilepsy. The clinical course varied remarkably and could be correlated with the molecular defects. The frequent pathogenic mutations p.R245H, p.Q380R, p.S66W, and c.1080delC were associated with the classical severe phenotype. Patients compound heterozygous for the p.S298P mutation in combination with 1 of the mutations associated with the classical severe phenotype had a significantly longer preservation of psychomotor functions and a longer survival. Two patients homozygous for the p.S298P mutation, and 4 patients from 3 families heterozygous for 3 missense variants not reported previously (p.T421R, p.P180L, and p.L12Q), showed a remarkably attenuated phenotype.

INTERPRETATION

We report the natural history and mutational analysis in a large unbiased cohort of MPS IIIA patients. We demonstrate that the clinical spectrum of MPS IIIA is much broader than previously reported. A significant genotype-phenotype correlation was established in this cohort.

摘要

目的

黏多糖贮积症 IIIA 型(Sanfilippo 综合征 A 型)是一种溶酶体贮积症,由磺基酯酶缺乏引起。由于新兴疗法的出现,黏多糖贮积症 IIIA 的自然病程信息非常缺乏,但又非常需要。

方法

通过酶学研究在荷兰鉴定的 110 例黏多糖贮积症 IIIA 患者的临床病史和分子缺陷均被收集并纳入本研究。

结果

首次临床症状主要包括语言发育迟缓、行为问题,发病年龄为 1 至 6 岁。其他症状包括睡眠和听力问题、复发性上呼吸道感染、腹泻和癫痫。临床过程差异显著,与分子缺陷相关。常见的致病性突变 p.R245H、p.Q380R、p.S66W 和 c.1080delC 与经典严重表型相关。复合杂合 p.S298P 突变与经典严重表型相关的 1 种突变的患者,精神运动功能保存和生存时间显著延长。2 例患者纯合 p.S298P 突变,3 个家系的 4 例患者杂合 3 种之前未报道的错义变异(p.T421R、p.P180L 和 p.L12Q),表现出明显减轻的表型。

解释

我们报告了一个大型、无偏倚的黏多糖贮积症 IIIA 患者队列的自然病史和突变分析。我们证明黏多糖贮积症 IIIA 的临床谱比之前报道的要广泛得多。本队列建立了显著的基因型-表型相关性。

相似文献

1
Mucopolysaccharidosis type IIIA: clinical spectrum and genotype-phenotype correlations.黏多糖贮积症 IIIA 型:临床谱及基因型-表型相关性。
Ann Neurol. 2010 Dec;68(6):876-87. doi: 10.1002/ana.22092.
2
Prediction of Sanfilippo phenotype severity from immunoquantification of heparan-N-sulfamidase in cultured fibroblasts from mucopolysaccharidosis type IIIA patients.通过对ⅢA型黏多糖贮积症患者培养成纤维细胞中乙酰肝素-N-硫酸酯酶进行免疫定量分析预测Sanfilippo综合征的表型严重程度
Mol Genet Metab. 2001 Aug;73(4):306-12. doi: 10.1006/mgme.2001.3190.
3
Sanfilippo syndrome in Turkey: Identification of novel mutations in subtypes A and B.土耳其的桑菲利波综合征:A 型和 B 型亚型中新突变的鉴定。
Hum Mutat. 2002 Feb;19(2):184-5. doi: 10.1002/humu.9009.
4
The mutation p.Ser298Pro in the sulphamidase gene (SGSH) is associated with a slowly progressive clinical phenotype in mucopolysaccharidosis type IIIA (Sanfilippo A syndrome).硫酸酰胺酶基因(SGSH)中的p.Ser298Pro突变与ⅢA型粘多糖贮积症(Sanfilippo A综合征)的缓慢进展临床表型相关。
Hum Mutat. 2008 May;29(5):770. doi: 10.1002/humu.20738.
5
Identification of 16 sulfamidase gene mutations including the common R74C in patients with mucopolysaccharidosis type IIIA (Sanfilippo A).在ⅢA型黏多糖贮积症(Sanfilippo A)患者中鉴定出16种硫酸酰胺酶基因突变,包括常见的R74C突变。
Hum Mutat. 1997;10(6):479-85. doi: 10.1002/(SICI)1098-1004(1997)10:6<479::AID-HUMU10>3.0.CO;2-X.
6
Molecular genetics of mucopolysaccharidosis type IIIA and IIIB: Diagnostic, clinical, and biological implications.ⅢA型和ⅢB型黏多糖贮积症的分子遗传学:诊断、临床及生物学意义
Hum Mutat. 2001 Oct;18(4):264-81. doi: 10.1002/humu.1189.
7
Cloning of the sulphamidase gene and identification of mutations in Sanfilippo A syndrome.硫酸酰胺酶基因的克隆及Sanfilippo A综合征突变的鉴定。
Nat Genet. 1995 Dec;11(4):465-7. doi: 10.1038/ng1295-465.
8
Residual activity and proteasomal degradation of p.Ser298Pro sulfamidase identified in patients with a mild clinical phenotype of Sanfilippo A syndrome.鉴定出 Sanfilippo A 综合征轻度临床表型患者中 p.Ser298Pro 芳基硫酸酯酶的残留活性和蛋白酶体降解。
Am J Med Genet A. 2011 Jul;155A(7):1634-9. doi: 10.1002/ajmg.a.34053. Epub 2011 Jun 10.
9
Clinical and genetic spectrum of Sanfilippo type C (MPS IIIC) disease in The Netherlands.荷兰Sanfilippo C型(MPS IIIC)疾病的临床和基因谱。
Mol Genet Metab. 2008 Feb;93(2):104-11. doi: 10.1016/j.ymgme.2007.09.011. Epub 2007 Nov 19.
10
Sanfilippo syndrome type D: natural history and identification of 3 novel mutations in the GNS Gene.D型桑菲利波综合征:自然病史及GNS基因中3个新突变的鉴定
Arch Neurol. 2007 Nov;64(11):1629-34. doi: 10.1001/archneur.64.11.1629.

引用本文的文献

1
Genetic Insights and Diagnostic Challenges in Highly Attenuated Lysosomal Storage Disorders.高度衰减型溶酶体贮积症的遗传学见解与诊断挑战
Genes (Basel). 2025 Jul 30;16(8):915. doi: 10.3390/genes16080915.
2
Clinical, biochemical, and molecular characteristics of Sanfilippo a syndrome (MPS IIIA) in a cohort of Egyptian patients.一组埃及患者中桑菲利波A综合征(MPS IIIA)的临床、生化和分子特征
Orphanet J Rare Dis. 2025 Aug 25;20(1):454. doi: 10.1186/s13023-025-03971-2.
3
Exploring Molecular and Phenotypic Characteristics of Arg234Gly and Asp312Asn Variants.
探索Arg234Gly和Asp312Asn变体的分子和表型特征。
Mol Syndromol. 2025 Aug;16(4):342-353. doi: 10.1159/000542367. Epub 2024 Nov 6.
4
Acute transient psychotic episode as presenting sign of Mucopolysaccharidosis III A (Sanfilippo Syndrome type A) in an adolescent patient.急性短暂性精神病发作作为一名青少年患者黏多糖贮积症 III A 型(A型桑菲利波综合征)的首发症状。
Eur Child Adolesc Psychiatry. 2025 Jun 16. doi: 10.1007/s00787-025-02764-z.
5
VarMeter2: An enhanced structure-based method for predicting pathogenic missense variants through Mahalanobis distance.VarMeter2:一种基于结构的增强型方法,通过马氏距离预测致病性错义变异。
Comput Struct Biotechnol J. 2025 Mar 1;27:1034-1047. doi: 10.1016/j.csbj.2025.02.008. eCollection 2025.
6
D1 dopamine receptor antagonists as a new therapeutic strategy to treat autistic-like behaviours in lysosomal storage disorders.D1多巴胺受体拮抗剂作为治疗溶酶体贮积症中自闭症样行为的一种新治疗策略。
Mol Psychiatry. 2025 Jan 26. doi: 10.1038/s41380-025-02904-6.
7
Advances in AAV-mediated gene replacement therapy for pediatric monogenic neurological disorders.腺相关病毒介导的小儿单基因神经疾病基因替代疗法的进展
Mol Ther Methods Clin Dev. 2024 Oct 16;32(4):101357. doi: 10.1016/j.omtm.2024.101357. eCollection 2024 Dec 12.
8
Evaluation of neuroretina following i.v. or intra-CSF AAV9 gene replacement in mice with MPS IIIA, a childhood dementia.MPS IIIA 型幼年痴呆症小鼠静脉内或鞘内 AAV9 基因替代治疗后神经视网膜评估。
CNS Neurosci Ther. 2024 Aug;30(8):e14919. doi: 10.1111/cns.14919.
9
Systemic immune challenge exacerbates neurodegeneration in a model of neurological lysosomal disease.系统性免疫挑战加重神经溶酶体疾病模型中的神经退行性变。
EMBO Mol Med. 2024 Jul;16(7):1579-1602. doi: 10.1038/s44321-024-00092-4. Epub 2024 Jun 18.
10
Clinical and Molecular Characterization of Mucopolysaccharidosis Type 3A and 3B in a Turkish Series.土耳其一组黏多糖贮积症3A型和3B型的临床与分子特征
Mol Syndromol. 2024 Jun;15(3):194-201. doi: 10.1159/000535888. Epub 2024 Jan 16.